Liminal Biosciences Inc

+0.11 (+2.65%)

Liminal Announces Resubmission Of Biologics License Application To U.S. FDA For Ryplazim

Published: 09/08/2020 11:01 GMT
Liminal Biosciences Inc (LMNL) - Liminal Biosciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency.
Liminal Biosciences Inc - Results From Pivotal Phase 2/3 Study Met Co-primary Endpoints.
Liminal - Believes Amended Bla Represents a Class 2 Resubmission That Would Provide for PDUFA Date Within 6 Months From Date of Resubmission.